OBJECTIVES: To assess the validity of the Filipino-translated version of the Michigan Neuropathy Screening Instrument(MNSI) in screening for diabetic neuropathy among Filipino patients with diabetes mellitus using nerve conduction velocity(NCV) as gold standard and to determine the most accurate cut-off score for the diagnosis of neuropathy using MNSI.
METHODOLOGY: A cross-sectional analytic study was done among adult diabetic patients. The original MNSI Questionnaire was translated and back-translated to the Filipino language. Each patient answered the Filipino version of MNSI Questionnaire followed by a lower extremity examination done by the investigator. All patients underwent NCV as reference standard. Sensitivity and specificity of MNSI were determined.
RESULTS: We studied a total of 150 subjects. Eighty-seven (58%) were diagnosed to have diabetic neuropathy based on NCV. The sensitivity and specificity of the MNSI Questionnaire improved to 73.6% and 52.4% respectively when the cut off was reduced to ?4, whereas for the MNSI Examination, the sensitivity and specificity improved to 86.2% and 55.6% respectively when the cut off was reduced to ?1. Combining both MNSI Questionnaire and MNSI Examination further improves the sensitivity to 95.4% whereas specificity is at 39.7%.
CONCLUSION: The analyses in 150 subjects confirm that the Filipino-version of MNSI is a valid screening tool for diabetic neuropathy when compared with NCV as gold standard.

Human ; Male ; Female ; Adult ; Questionnaires ; Diabetes Mellitus ; Philippines ; Patients

BACKGROUND: Antibodies to neuronal extracellular membrane antigens, including the NR1 subunit of the N-methyl-D-aspartate receptor, have been associated with neuropsychiatric symptoms. In 2003, the first case of anti-NMDA receptor encephalitis was identified in a young woman with subacute onset of ehavioural changes and seizures.
OBJECTIVES: The aim of this case report is to describe the clinical features, disease course and management of a documented case of anti-NMDA receptor encephalitis in the Philippines. It also aims to highlight a unique feature of the disease as seen in the patient.
CASE DESCRIPTION: The patient is a 36-year-old female with no known co-morbidities presenting with subacute onset of ehavioural change and generalized seizures. She was initially worked-up for viral encephalitis but the diagnostic tests were negative. With a suspicion of anti-NMDA receptor encephalitis, a search was made for the presence of a teratoma. This was confirmed by imaging studies and subsequent surgical resection of an immature mesenteric teratoma was done. Immunohistochemical assay of both blood and CSF were positive for NMDAR antibodies.
CONCLUSION: This is the first confirmed case of anti-NMDA receptor encephalitis reported in the Philippines. It has the unique feature of being associated with an immature mesenteric teratoma, a finding that has not been reported in literature. The possibility of anti-NMDAR encephalitis need to be considered among patients with subacute onset of ehavioural changes and seizures when usual diagnostic tests for the more common etiologies prove negative.

Human ; Female ; Adult ; Anti-n-methyl-d-aspartate Receptor Encephalitis ; Antibodies ; Encephalitis, Viral ; Mesentery ; Receptors, N-methyl-d-aspartate ; Teratoma

INTRODUCTION: Intravenous administration of Recombinant Tissue Plasminogen Activator (IV-rTPA) has been an essential component of reperfusion treatment strategies in the aftermath of the 1995 National Institute of Neurological Disorders and Stroke (NINDS) TPA Stroke Study. However, it remains to be under-utilized both nationally and worldwide. Local data on thrombolytic use are very limited.

OBJECTIVES: This study aims to document our institution's experience with the use of intravenous thrombolysis in acute ischemic stroke cases by describing the demographic, clinical, radiographic, and management profiles of all our patients who were given IV - rTPA and their functional outcomes upon discharge and after three months.

METHOD: This is a descriptive study utilizing a clinical series design. Chart review of eighteen (18) patients who were admitted in our institution--a tertiary private hospital--due to acute ischemic stroke from January 2007 to August 2009 and who has given IV- rTPA was done. The patients' functional outcomes measured by the Modified Rankin Scale (MRS) upon discharge and at three months after stroke onset were documented by reviewing the patients' inpatient and outpatient records and by telephone interview conducted with the patients and/or their relatives.

RESULTS: The mean age of patients thrombolysed in our institution was 57.11 + 13.5 years (range: 31 to 80 years). All cases, except for one vertebrobasilar stroke, were anterior circulation strokes. Mean ictus-to-needle time frame for all thrombolysed patients was 174.3 + 56.6 minutes. The mean rTPA dose given to our patients was 0.87 + 0.08 mg/kg. A total 77.8% patients (14 of 18) received the standard rTPA dose of 0/9 mg/kg. Fourteen patients had follow-up imaging post-rTPA. Among these, 21.4% (3 of 14) developed non-symptomatic intracerebral hemorrhage (NSICH); 7.1% (1 of 14) developed a fatal symptomatic intracerebral hemorrhage (SICH). The mean baseline National Institutes of Health Stroke Scale (NIHSS) score of all patients was 14.9 + 5.9 (range: 4 to 24). Mean NIHSS score within the first 24 hours post-rTPA was 8.8 ± 6.1 (range: 0 to 19)--a 41% improvement from baseline. Eleven patients (11 of 18) or 61.1% were noted to have early improvement or an improvement of NIHSS score within the first 24 hours by ≥ 4. The mean follow-up NIHSS score beyond the first 24 hours post-rTPA was 5.5 ± 5.3 (range: 0 to 18), obtained at an average of 4.8 ± 2.4 days post-thrombolysis--a 63% improvement from the baseline mean NIHSS score. The mean MRS score of all patients upon hospital discharge was 3.17 ± 1.69. Two patients (2 of 18) or 11.1% expired 4 and 5 days post-thrombolysis; two (2 of 18) were lost to follow-up. For those who survived to discharge and not lost to follow-up (n=14), the mean MRS score at three months was noted to be 1.50 ± 1.09--a 53% improvement from mean MRS upon discharge. Seven of 18 patients (39%) had a favorable outcome defined as MRS ≤ 1 at three months post thrombolysis. Protocol deviations in our hospital were reported in 16.7% (3 of 18).

CONCLUSION: Our study showed trends to early improvement and favorable outcomes among stroke patients given IV-rTPA within 3 to 4.5 hours from ictus in our institution--with NIHSS scores improving by 40 to 60% during the course of their hospital stay, and 39% of patients having minimal or no disability at 3 months using the MRS. Our institution has more experience the standard rTPA dose of 0.9 mg/kg. A hospital brain rack team (BAT) that is on-call 24 hours' aids in the facilitation of thrombolytic treatment in acute ischemic strokes.

Human ; Aged 80 And Over ; Tissue Plasminogen Activator ; National Institute Of Neurological Disorders And Stroke (u.s.) ; Stroke ; Length Of Stay ; Brain Ischemia ; Inpatients ; Outpatients ; Follow-up Studies ; Lost To Follow-up ; Fibrinolytic Agents ; Cerebral Hemorrhage ; Reperfusion ; Administration, Intravenous ; Brain ; Hospitals, Private ; Demography ; Telephone